About Lineagen
Lineagen is a company based in Salt Lake City (United States) founded in 2002 was acquired by Bionano Genomics in August 2020. Lineagen has raised $66.93 million across 7 funding rounds from investors including Hatteras Funds, Petra Capital Partners and Health Quest Capital. The company has 40 employees as of December 31, 2022. Lineagen offers products and services including FirstStep Dx PLUS, NextStep Dx PLUS, OGM-Dx Postnatal Whole Genome SV, and OGM-Dx Prenatal Whole Genome SV. Lineagen operates in a competitive market with competitors including Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
- Headquarter Salt Lake City, United States
- Employees 40 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Lineagen Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$66.93 M (USD)
in 7 rounds
-
Latest Funding Round
$12.17 M (USD), Series C
Jan 26, 2015
-
Investors
Hatteras Funds
& 11 more
-
Employee Count
40
as on Dec 31, 2022
-
Acquired by
Bionano Genomics
(Aug 24, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Lineagen
Lineagen offers a comprehensive portfolio of products and services, including FirstStep Dx PLUS, NextStep Dx PLUS, OGM-Dx Postnatal Whole Genome SV, and OGM-Dx Prenatal Whole Genome SV.
Diagnostic test for pediatric neurodevelopmental disorders using chromosomal microarray.
Service for whole exome sequencing to identify genetic variants.
Assessment of structural variants in postnatal genome testing.
Prenatal testing for genome structural variants.
Funding Insights of Lineagen
Lineagen has successfully raised a total of $66.93M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $12.17 million completed in January 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Lineagen
Lineagen has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Hatteras Funds, Petra Capital Partners and Health Quest Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity fund.
|
Locked | Locked | Locked | |
|
Investments are focused on tech and life sciences startups.
|
Locked | Locked | Locked | |
|
Venture capital is directed toward life sciences and technology sectors.
|
Locked | Locked | Locked |
Investor details for Lineagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lineagen
Investment portfolio details for Lineagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Lineagen
Detailed financials for Lineagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Lineagen Comparisons
Peer comparison for Lineagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Lineagen
Lineagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Invitae, Myriad Genetics, Genome Medical, Centogene and Fulgent Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Molecular diagnostics and personalized medicine for cancer are developed.
|
|
| Locked | Locked | Locked |
Genomic testing services are provided clinically and directly to consumers.
|
|
| Locked | Locked | Locked |
Provider of biochemical/genetic tests to detect mutations and rare diseases
|
|
| Locked | Locked | Locked |
Provider of genetic testing services for carrier screening cardiovascular diseases, epilepsy and cancer
|
|
| Locked | Locked | Locked |
High-throughput gene sequencing platform is developed for clinical diagnostics.
|
Detailed competitors of Lineagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Lineagen
Complete news archive for Lineagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lineagen
Lineagen was founded in 2002 and raised its 1st funding round 8 years after it was founded.
Lineagen is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Lineagen is a funded company, having raised a total of $66.93M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Lineagen is 40.
Lineagen was founded in 2002 and is based in Salt Lake City, United States. Diagnostic tests based on sequencing technology, along with consultative services, are offered to physicians evaluating children with autism or developmental delays. Support is extended to parents through these resources. Digital platforms including m-chat.org for online screening tools and OpenAutism.com for specialist information exchange are maintained in the healthcare sector focused on neurodevelopmental disorders.
Lineagen's top competitors include Fulgent Genetics, Centogene and Myriad Genetics.
Lineagen offers FirstStep Dx PLUS, NextStep Dx PLUS, OGM-Dx Postnatal Whole Genome SV, and OGM-Dx Prenatal Whole Genome SV.
Lineagen has 12 investors. Key investors include Hatteras Funds, Petra Capital Partners, Health Quest Capital, Mountain Group Partners, and Sanderling Ventures.